Antipsychotic-induced hyperprolactinaemia in patients with schizophrenia: Considerations in relation to bone mineral density

Journal of Psychiatric and Mental Health Nursing

Volumn 16, Issue 9, 2009, Pages 838-842

  Stubbs, B ^a,b  

^a Gallowgate House   (United Kingdom)

^b NONE   (United Kingdom)

Author keywords

Antipsychotic medication; Hyperprolactinaemia; Osteoporosis; Physical health considerations into nursing practice; Schizophrenia

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; BONE DENSITY; CHEMICALLY INDUCED DISORDER; FRACTURE; HUMAN; HYPERPROLACTINEMIA; OSTEOPOROSIS; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PSYCHOLOGICAL ASPECT; PSYCHOLOGY; RISK FACTOR; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BONE DENSITY; FRACTURES, BONE; HUMANS; HYPERPROLACTINEMIA; OSTEOPOROSIS; RISK FACTORS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 70350022262     PISSN: 13510126     EISSN: 13652850     Source Type: Journal    
DOI: 10.1111/j.1365-2850.2009.01472.x     Document Type: Article

References (35)

1. Beaumont P.J.V., Geider M.G., Friesen H.G., et al. (1974) The effects of phenothiazines on endocrine function. Patients with inappropriate lactation and amenorrhea. British Journal of Psychiatry 124, 413 419.
2. Bushe C. Shaw M. (2007) Prevalence of hyperprolacatinaemia in a naturalistic cohort of schizophrenia and bipolar outpatients during treatment with typical and afirst generation antipsychotics. Journal of Psychopharmacology 21, 768 773.
3. Bushe C.M., Shaw M. Peveler R.C. (2008a) A review of the association between antipsychotic use and hyperprolactinaemia. Journal of Psychopharmacology 22, 46 55.
4. Bushe C.M., Yeomans D., Floyd T., et al. (2008b) Categorical prevalence and severity of hyperprolactinaemia in two UK cohorts of patients with severe mental illness during treatment with antipsychotics. Journal of Psychopharmacology 22, 56 62.
5. Coss D., Yang L., Kuo C.B., et al. (2000) Effects of prolactin on osteoblast alkaline phosphate and bone formation in the developing rat. American Journal of Physiology, Endocrine & Metabolism 279, E1216 E1225.
6. Daniel H.W. (1976) Osteoporosis of the slender smoker. Archives Internal Medicine 136, 298 304.
7. Goff D.C., Henderson D.C. Amico E. (1992) Cigarette smoking in schizophrenia: relationship to psychopathology and medication side effects. American Journal of Psychiatry 149, 1189 1194.
8. Haddad P.M. Wieck A. (2004) Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64, 2291 2314.
9. Halbreich U., Kinon B.J., Gilmore J.A., et al. (2003) Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychneuroendocrinology 28, 53 67.
10. Hobson E.E. Ealston S.H. (2001) Role of genetic factors in the pathophysiology and management of osteoporosis. Clinical Endocrinology (Oxford) 54, 1 9.
11. Holt R.I.G. (2008) Medical causes and consequences of hyperprolactinaemia. A context for psychiatrists. Journal of Psychopharmacology 22, 28 37.
12. Howard L., Kirkwood G. Leese M. (2007) Risk of hip fracture in patients with a history of schizophrenia. British Journal of Psychiatry 190, 129 134.
13. Hummer M., Malik P., Gasser R.W., et al. (2005) Osteoporosis in patients with Schizophrenia. American Journal of Psychiatry 162, 162 167.
14. Jung D.U., Seo Y.S., Park J.H., et al. (2005) The prevalence of hyperprolactinemia after long-term haloperidol use in patients with chronic schizophrenia. Journal of Clinical Psychopharmacology 25, 613 615.
15. Jung D.U., Conley R.R., Kelly D.L., et al. (2006) Prevalence of bone mineral density loss in Korean patients with schizophrenia: a cross sectional study. Journal of Clinical Psychiatry 67, 1391 1396.
16. Kleinberg D.L., Davis J.M., de Coster R., et al. (1999) Prolactin levels and adverse events in patients treated with risperidone. Journal of Clinical Psychopharmacology 19, 57 61.
17. Kohen D. Wildgust H.M. (2008) The evolution of hyperprolcatinaemia as an entity in psychiatric patients. Journal of Psychopharmacology 22, 6 11.
18. Law M.R. Hackshaw A.K. (1997) A meta-analysis of cigarette smoking, bone mineral density and risk of hip fracture: recognition of a major effect. BMJ 315, 841 846.
19. Linkowski P., Van Cauter E., L'Hermite-Baleriaux M., et al. (1989) The 24-hour profile of plasma prolactin in men with major endogenous depressive illness. Archives of General Psychiatry 46, 813 819.
20. Liu H., Paige N.M., Goldzweig C.L., et al. (2008) Screening for osteoporosis in men: a systematic review for an American College of Physicians guideline. Annals of Internal Medicine 148, 685 701.
21. Marder S.R., Essock S.M., Miller A.L., et al. (2004) Physical health monitoring of patients with schizophrenia. The American Journal of Psychiatry 161, 1334 1349.
22. Meaney A.M. O'Keane V. (2007) Bone mineral density changes over a year in young females with schizophrenia: relationship to medication and endocrine variables. Schizophrenia Research 93, 136 143.
23. Michelson D., Stratakis C., Hill L., et al. (1996) Bone mineral density in women with depression. New England Journal of Medicine 335, 1176 1181.
24. Montgomery J., Winterbottom E., Jessani M., et al. (2004) Prevalence of hyperprolactinaemia in schizophrenia: association with atypical and typical antipsychotic treatment. Journal of Clinical Psychiatry 65, 1491 1498.
25. Naidoo U., Goff D.C. Klibanski A. (2003) Hyperprolactinaemia and bone mineral density: the potential impact of antipsychotic agents. Psychoneuroendocrinology 28, 97 108.
26. O'Keane V. Meaney A.M. (2005) Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia? Journal of Clinical Psychiatry 25, 26 31.
27. Osteoporosis Consensus Statement (2000) Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement (Online) 17, 1 36 (accessed on 01/06/2009).
28. Peveler R.C., Branford D., Citrome L., et al. (2008) Antipsychotics and hyperprolactinaemia: clinical recommendations. Journal of Psychopharmacology 22, 98 103.
29. Schooler N., Rabinowitz J., Davidson M., et al. (2005) Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial. The American Journal of Psychiatry 162, 947 953.
30. Stubbs B., Zapata-Bravo E. Haw C. (2009) Screening for osteoporosis: a survey of older psychiatric inpatients at a tertiary referral centre. International Psychogeriatrics 21, 180 186.
31. Tyler C.V., Snyder C.W. Zyzanski S. (2000) Screening for osteoporosis in community-dwelling adults with mental retardation. Mental Retardation 38, 316 321.
32. Wieck A. Haddad P. (2002) Hyperprolactinaemia caused by antipsychotic drugs. BMJ 324, 250 252.
33. Wieck A. Haddad P.M. (2003) Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity, and consequences. British Journal of Psychiatry 182, 199 204.
34. World Health Organisation (1994) Assessment of Fracture Risk and Its Application to Screening for Osteoporosis for Postmenopausal Osteoporosis. In technical report series 843. WHO, Geneva.
35. Yirmiya R., Goshen I., Bajayo A., et al. (2006) Depression induces bone loss through stimulation of the sympathetic nervous system. Proceedings of the National Academy of Sciences of the United States of America 103, 16876 16881.